Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
After finishing at $2.53 in the prior trading day, Clover Health Investments Corp (NASDAQ: CLOV) closed at $2.59, up 2.37%. In other words, the price has increased by $2.37 from its previous closing price. On the day, 10.0 million shares were traded. CLOV stock price reached its highest trading level at $2.645 during the session, while it also had its lowest trading level at $2.51.
Ratios:
Our goal is to gain a better understanding of CLOV by taking a closer look at its different ratios. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Craig Hallum on December 17, 2024, initiated with a Buy rating and assigned the stock a target price of $6.
On October 07, 2024, UBS started tracking the stock assigning a Neutral rating and target price of $4.
Cowen Upgraded its Underperform to Market Perform on February 02, 2022, whereas the target price for the stock was revised from $7 to $3.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 17 ’25 when Reynoso Jamie L. sold 4,914 shares for $3.09 per share. The transaction valued at 15,184 led to the insider holds 3,053,890 shares of the business.
JAMIE REYNOSO bought 4,914 shares of CLOV for $15,332 on Sep 17 ’25. On Aug 13 ’25, another insider, Loengard Anna U, who serves as the Director of the company, bought 26,500 shares for $2.59 each. As a result, the insider paid 68,755 and bolstered with 29,610 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CLOV now has a Market Capitalization of 1327407488 and an Enterprise Value of 1126135552. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.83 while its Price-to-Book (P/B) ratio in mrq is 3.63. Its current Enterprise Value per Revenue stands at 0.7 whereas that against EBITDA is -27.426.
Stock Price History:
The Beta on a monthly basis for CLOV is 2.08, which has changed by -0.29810297 over the last 52 weeks, in comparison to a change of 0.17904854 over the same period for the S&P500. Over the past 52 weeks, CLOV has reached a high of $4.87, while it has fallen to a 52-week low of $2.12. The 50-Day Moving Average of the stock is -7.35%, while the 200-Day Moving Average is calculated to be -22.75%.
Shares Statistics:
The stock has traded on average 8.47M shares per day over the past 3-months and 11497670 shares per day over the last 10 days, according to various share statistics. A total of 390.25M shares are outstanding, with a floating share count of 384.65M. Insiders hold about 24.95% of the company’s shares, while institutions hold 28.75% stake in the company. Shares short for CLOV as of 1757894400 were 49278776 with a Short Ratio of 5.82, compared to 1755216000 on 50279320. Therefore, it implies a Short% of Shares Outstanding of 49278776 and a Short% of Float of 12.049999999999999.
Earnings Estimates
The performance of Clover Health Investments Corp (CLOV) in the stock market is under the watchful eye of 1.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is $0.0, with high estimates of $0.0 and low estimates of $0.0.
Analysts are recommending an EPS of between $0.1 and $0.1 for the fiscal current year, implying an average EPS of $0.1. EPS for the following year is $0.19, with 1.0 analysts recommending between $0.19 and $0.19.
Revenue Estimates
4 analysts predict $467.18M in revenue for. The current quarter. It ranges from a high estimate of $475.4M to a low estimate of $455.43M. As of. The current estimate, Clover Health Investments Corp’s year-ago sales were $330.99MFor the next quarter, 4 analysts are estimating revenue of $472.87M. There is a high estimate of $486.6M for the next quarter, whereas the lowest estimate is $460.75M.
A total of 4 analysts have provided revenue estimates for CLOV’s current fiscal year. The highest revenue estimate was $1.9B, while the lowest revenue estimate was $1.86B, resulting in an average revenue estimate of $1.88B. In the same quarter a year ago, actual revenue was $1.37BBased on 4 analysts’ estimates, the company’s revenue will be $2.42B in the next fiscal year. The high estimate is $2.6B and the low estimate is $2.25B.
